Phaseline

Companies › Trust Bio-sonics

Trust Bio-sonics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NH002
Perflutren lipid microspheres contrast agent for echocardiography
–Phase 3Cardiac DiseasesFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06815627NH002Phase 3Cardiac DiseasesCardiovascularFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Liquidia Technologies EVD Pharmacy and Medical Company Pulmovant EBI Anti Sepsis Agitated Solutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.